Review decision, February 2007
Review of NICE Technology Appraisal Guidance No 86, on the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Following consultation, all the comments received, have led to the agreement that the Institute should proceed with a review of the existing guidance on the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.
We are currently in discussion with the manufacturer of imatinib to agree the most appropriate timing for updating the existing guidance. Consultees and Commentators will be contacted when the timing has been confirmed.
20 February 2007
This page was last updated: 30 December 2010